CRISPR Therapeutics AG (NASDAQ:CRSP) Shares Sold by E Fund Management Co. Ltd.

E Fund Management Co. Ltd. reduced its stake in CRISPR Therapeutics AG (NASDAQ:CRSP) by 14.2% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 11,785 shares of the company’s stock after selling 1,951 shares during the quarter. E Fund Management Co. Ltd.’s holdings in CRISPR Therapeutics were worth $464,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in the stock. Capital Market Strategies LLC purchased a new position in shares of CRISPR Therapeutics during the fourth quarter worth $461,000. KBC Group NV lifted its stake in CRISPR Therapeutics by 2,047.4% during the 4th quarter. KBC Group NV now owns 60,514 shares of the company’s stock worth $2,382,000 after acquiring an additional 57,696 shares in the last quarter. Geode Capital Management LLC grew its position in CRISPR Therapeutics by 3.6% in the 3rd quarter. Geode Capital Management LLC now owns 1,008,214 shares of the company’s stock valued at $47,383,000 after acquiring an additional 35,196 shares in the last quarter. State Street Corp increased its stake in CRISPR Therapeutics by 25.0% during the third quarter. State Street Corp now owns 2,992,988 shares of the company’s stock worth $140,611,000 after purchasing an additional 599,304 shares during the period. Finally, ARK Investment Management LLC lifted its position in shares of CRISPR Therapeutics by 19.7% during the fourth quarter. ARK Investment Management LLC now owns 8,973,064 shares of the company’s stock worth $353,180,000 after purchasing an additional 1,474,439 shares in the last quarter. Institutional investors and hedge funds own 69.20% of the company’s stock.

CRISPR Therapeutics Price Performance

Shares of NASDAQ:CRSP opened at $45.53 on Friday. CRISPR Therapeutics AG has a 12 month low of $36.52 and a 12 month high of $81.73. The firm has a market capitalization of $3.91 billion, a P/E ratio of -10.42 and a beta of 1.77. The company’s fifty day moving average price is $42.79 and its 200 day moving average price is $45.77.

CRISPR Therapeutics (NASDAQ:CRSP) last posted its earnings results on Tuesday, February 11th. The company reported ($0.44) EPS for the quarter, topping analysts’ consensus estimates of ($1.15) by $0.71. CRISPR Therapeutics had a negative return on equity of 18.46% and a negative net margin of 981.54%. On average, sell-side analysts anticipate that CRISPR Therapeutics AG will post -5.16 EPS for the current year.

Insiders Place Their Bets

In related news, CEO Samarth Kulkarni sold 18,360 shares of the stock in a transaction on Wednesday, February 19th. The shares were sold at an average price of $55.20, for a total transaction of $1,013,472.00. Following the completion of the sale, the chief executive officer now owns 171,613 shares in the company, valued at $9,473,037.60. This represents a 9.66 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director John Greene acquired 7,000 shares of the company’s stock in a transaction on Wednesday, February 26th. The stock was acquired at an average price of $44.85 per share, for a total transaction of $313,950.00. Following the completion of the purchase, the director now owns 7,000 shares of the company’s stock, valued at $313,950. This trade represents a ∞ increase in their position. The disclosure for this purchase can be found here. 4.10% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

CRSP has been the subject of a number of research reports. Truist Financial lifted their price objective on shares of CRISPR Therapeutics from $100.00 to $120.00 and gave the company a “buy” rating in a report on Wednesday, February 12th. Morgan Stanley upped their price objective on CRISPR Therapeutics from $30.00 to $32.00 and gave the stock an “underweight” rating in a research report on Friday, February 14th. HC Wainwright reiterated a “buy” rating and issued a $65.00 price objective on shares of CRISPR Therapeutics in a research note on Thursday, February 13th. Royal Bank of Canada cut their price target on CRISPR Therapeutics from $53.00 to $48.00 and set a “sector perform” rating on the stock in a report on Wednesday, February 12th. Finally, Stifel Nicolaus decreased their price objective on CRISPR Therapeutics from $53.00 to $49.00 and set a “hold” rating for the company in a research note on Thursday, February 13th. Two equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and eleven have given a buy rating to the stock. According to data from MarketBeat.com, CRISPR Therapeutics currently has a consensus rating of “Hold” and an average target price of $73.11.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.